Wealthfront Advisers LLC Purchases New Holdings in Sanofi (NASDAQ:SNY)

Wealthfront Advisers LLC purchased a new stake in shares of Sanofi (NASDAQ:SNY) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor purchased 39,551 shares of the company’s stock, valued at approximately $1,908,000.

Several other hedge funds also recently added to or reduced their stakes in SNY. Abel Hall LLC grew its stake in Sanofi by 1.8% in the 4th quarter. Abel Hall LLC now owns 10,990 shares of the company’s stock worth $530,000 after acquiring an additional 194 shares in the last quarter. Keudell Morrison Wealth Management grew its stake in Sanofi by 1.7% in the 4th quarter. Keudell Morrison Wealth Management now owns 12,928 shares of the company’s stock worth $624,000 after acquiring an additional 217 shares in the last quarter. Bailard Inc. grew its stake in Sanofi by 1.4% in the 4th quarter. Bailard Inc. now owns 16,359 shares of the company’s stock worth $789,000 after acquiring an additional 220 shares in the last quarter. Old Port Advisors grew its stake in Sanofi by 0.6% in the 4th quarter. Old Port Advisors now owns 36,704 shares of the company’s stock worth $1,770,000 after acquiring an additional 232 shares in the last quarter. Finally, ORG Partners LLC grew its stake in Sanofi by 17.7% in the 4th quarter. ORG Partners LLC now owns 1,681 shares of the company’s stock worth $81,000 after acquiring an additional 253 shares in the last quarter. 14.04% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on SNY. Sanford C. Bernstein upgraded shares of Sanofi to a “strong-buy” rating in a research note on Thursday, January 30th. StockNews.com downgraded shares of Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a “sell” rating to a “hold” rating in a research note on Thursday, January 30th. Two investment analysts have rated the stock with a hold rating, one has issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Buy” and an average target price of $60.00.

Sanofi Price Performance

Shares of SNY opened at $57.75 on Friday. The company has a 50 day moving average price of $53.65 and a 200-day moving average price of $52.86. Sanofi has a fifty-two week low of $45.22 and a fifty-two week high of $60.12. The stock has a market capitalization of $146.56 billion, a PE ratio of 23.19, a PEG ratio of 1.01 and a beta of 0.58. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.14 and a current ratio of 1.46.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings results on Thursday, January 30th. The company reported $0.70 earnings per share for the quarter, hitting the consensus estimate of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. Equities analysts predict that Sanofi will post 4.36 earnings per share for the current fiscal year.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.